Epitopea Strikes Research Collaboration with Merck, Appoints Klaus Edvardsen as Chief Medical Officer
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.
Image Credit: Adobe Stock Images/GulzarHussain
Epitopea, a transatlantic cancer immunotherapeutics company specializing in RNA-based immunotherapies, has announced two recent major developments to facilitate the company’s growth.
Epitopea has entered into a license and research collaboration agreement with Merck to identify Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor. According to the company, non-mutated TSAs are discovered through its CryptoMap platform, revealing aberrantly expressed antigens derived from what is considered to be “junk DNA.”1
“Epitopea has been at the forefront of identifying Cryptigen TSAs, whose intratumor shared nature across patients has made them ideal targets for the development of off-the-shelf immunotherapies,” said Alan C. Rigby, CEO, Epitopea, in a press release. “At Epitopea, we continue to accelerate the development of our preclinical pipeline as we transition to a clinical-stage company on the ‘heels’ of our recent, oversubscribed, pre-Series A financing. We believe that this strategic collaborative relationship with MSD, a leader in immunotherapy therapeutic development, provides us with an additional opportunity to validate the potential impact of these differentiated tumor specific antigens. We are thrilled to collaborate with MSD as our teams collectively look to impact the lives of patients with cancer by helping to improve outcomes.”
Under terms of the agreement, Merck will obtain exclusive rights to develop and commercialize therapies stemming from the collaboration. Epitopea will receive a currently undisclosed upfront payment, with the potential to receive up to $300 million per product.1
“Despite the remarkable progress made in cancer treatment over the past decade, more therapeutic options are needed,” said George Addona, SVP, discovery, preclinical development and translational medicine, Merck Research Laboratories, in the press release. “We continue to explore new ways to build upon our strong foundation in immuno-oncology and look forward to collaborating with the Epitopea team.”
Epitopea also announced the appointment of Klaus Edvardsen, MD, PhD, as chief medical officer. Edvardsen previously served in several senior roles, most recently as chief development officer for Nykode Therapeutics, overseeing regulatory affairs, clinical development, and project management across oncology, infectious diseases, and autoimmune diseases. Additionally, Edvardsen worked as both chief medical officer and chief development officer at CureVac, as well as SVP and head of global oncology development at Merck Healthcare KgaA.2
“I am truly honored to join Epitopea at this pivotal time in its journey. The company’s pioneering work in leveraging Cryptigen as a novel class of tumor-specific antigens offers a unique opportunity to redefine cancer immunotherapy. I look forward to collaborating with Epitopea’s talented team to drive the development of transformational therapies that can address significant unmet needs for patients with hard-to-treat cancers,” Edvardsen said in a press release.
Notably, Edvardsen contributed to the development of therapies such as Tagrisso, Lynpara, and Calquence during his time as EVP and head of global medicines development oncology at AstraZeneca. Additionally, he was credited with securing the fastest FDA and EMA approval for Tagrisso in non-small cell lung cancer and in advancing Lynparza for multiple indications, including ovarian and metastatic breast cancers.2
“We are thrilled to welcome Klaus to our executive leadership team at such an important stage in Epitopea’s growth. Klaus’s experience and expertise in oncology drug development and his proven track record of leading innovative therapies from concept to regulatory approval will be instrumental as we advance our pipeline into clinical trials. His leadership undoubtedly strengthens our mission to develop durable, off-the-shelf cancer immunotherapies that can profoundly improve patient outcomes,” Rigby said in the release.
References
1. Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens. Epitopea. February 19, 2025. Accessed February 19, 2025. https://www.epitopea.com/epitopea-announces-license-and-research-collaboration-agreement-with-msd-to-identify-cryptigentm-tumor-specific-antigens/
2. Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer. Epitipea. February 7, 2025. Accessed February 19, 2025. https://www.epitopea.com/epitopea-appoints-klaus-edvardsen-m-d-ph-d-as-chief-medical-officer/
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
